Skip to content

Helping patients reclaim a life of possibility

Menu
  • About us
  • Contact us
logo MPE
  • Myeloma and AL Amyloidosis
    • About myeloma
    • About AL amyloidosis
  • What we do
      • Member and patient community programmes
        • Myeloma Awareness Month
        • MPE Masterclass
        • Scholarship programme
        • Care Connect Programme
        • Myeloma CABs
        • MPE Myeloma and AL amyloidosis Community Taskforce
        • Advocate Development Programme
        • European Young Myeloma Patients Group
        • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • Research
        • Patient Evidence
        • Horizon Europe
        • IMI
      • Access and Policy
        • Myeloma Access Atlas
        • CEE workgroup on Access
        • Myeloma and AL amyloidosis Clinical Trial Navigator
        • EU HTA regulation
    • Member and patient community programmes
      • MPE Masterclass
      • Scholarship programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • European Young Myeloma Patients Group
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access and Policy
      • Myeloma Access Atlas
      • CEE workgroup on Access
      • Myeloma and AL amyloidosis Clinical Trial Navigator
      • EU HTA regulation
  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Patient guides
  • European Myeloma Day
  • News
logo MPE
  • Myeloma and AL Amyloidosis
    • About myeloma
    • About AL amyloidosis
  • What we do
      • Member and patient community programmes
        • Myeloma Awareness Month
        • MPE Masterclass
        • Scholarship programme
        • Care Connect Programme
        • Myeloma CABs
        • MPE Myeloma and AL amyloidosis Community Taskforce
        • Advocate Development Programme
        • European Young Myeloma Patients Group
        • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • Research
        • Patient Evidence
        • Horizon Europe
        • IMI
      • Access and Policy
        • Myeloma Access Atlas
        • CEE workgroup on Access
        • Myeloma and AL amyloidosis Clinical Trial Navigator
        • EU HTA regulation
    • Member and patient community programmes
      • MPE Masterclass
      • Scholarship programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • European Young Myeloma Patients Group
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access and Policy
      • Myeloma Access Atlas
      • CEE workgroup on Access
      • Myeloma and AL amyloidosis Clinical Trial Navigator
      • EU HTA regulation
  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Patient guides
  • European Myeloma Day
  • News
logo MPE
Charlotte Haynes

CHARLOTTE HAYNES

Charlotte joined MPE as Scientific and Patient Information Manager in January 2026.

Charlotte holds a PhD and BSc in Experimental Psychology from the University of Sussex, and a Postgraduate Certificate in Public Health from the University of Manchester. She has over 20 years of experience in healthcare research, evidence synthesis, and scientific communication.

Before joining MPE, Charlotte worked for 13 years at the National Institute for Health and Care Excellence (NICE), a public body that develops independent, evidence-based guidance to improve health and social care in England. She also worked for eight years as Research and Projects Lead at a UK NHS foundation trust hospital. In these roles, she worked at the interface of science, policy, and communication, ensuring that evidence was accurately interpreted and translated into clear, practical recommendations for health and social care professionals, commissioners and managers, patients, service users and carers.

Charlotte has a strong commitment to patient-centred communication and to ensuring that information is inclusive and accessible for all patient populations. She currently lives in the North West of England. She speaks English fluently and French at an upper-intermediate level.

 

Recent Posts

Myeloma melodies is back in Paris

7 September 2026

Myeloma Melodies, an awareness concert for myeloma, returns to Paris on 24 September for an evening of singing, music and fun. The concert is organised by Sarah Tullamore, a professional…

Read more

Preview to members September activities across Europe

2 September 2026

September is shaping up to be an extraordinary month for myeloma awareness and advocacy across MPE’s member network. From Portugal to Serbia, from Lithuania to Slovenia, our members are planning…

Read more
Professor Phillipe Moreau

IMS President Philippe Moreau previews this months IMS Annual Meeting

2 September 2026

Myeloma Patients Europe (MPE) is attending and presenting at the International Myeloma Society (IMS) Annual Meeting taking place in Glasgow from 23–26 September 2026. The meeting, attended by over 3,000…

Read more

A young patient’s experience of induced menopause after myeloma treatment

2 September 2026

As part of our September European Young Myeloma Patients Group (EYMPG) meeting on Induced Menopause and Sexual Health in young myeloma patients, Filipa Lopes has shared her personal experience of…

Read more

EMA committee recommends teclistamab plus daratumumab for relapsed or refractory multiple myeloma

3 July 2026

On 25 June 2026, the Committee for Medicinal Products for Human Use (CHMP) recommended extending the approved use of teclistamab (Tecvayli®) to include its use in combination with daratumumab for…

Read more

MPE joins patient organisations call for stronger patient voice in EU health technology assessments

1 July 2026

Myeloma Patients Europe has joined 14 other patient organisations members of the European Union Health Technology Assessment (EUHTA) stakeholder network to issue a joint statement on the publication of the…

Read more
mpe logo negativo 300x249 1

Myeloma Patients Europe AISBL

Avenue Louise 143/4, 1050
Brussels Belgium
© Myeloma Patients Europe 2026
  • Contact
  • About us
  • Privacy policy
  • Terms and conditions
  • Cookies Policy
Go to Top
logo MPE
  • About MPE
    • Our members
    • Our board and staff
    • Medical Advisory Committee
    • Our Strategic Goals
    • Our funding
    • Get involved in MPE activities
    • Become a member
  • Contact us
  • Myeloma and AL Amyloidosis
    • About myeloma
    • About AL amyloidosis
  • What we do
    • Member and patient community programmes
      • Myeloma Awareness Month
      • MPE Masterclass
      • Scholarship programme
      • Care Connect Programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • European Young Myeloma Patients Group
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access and Policy
      • Myeloma Access Atlas
      • CEE workgroup on Access
      • Myeloma and AL amyloidosis Clinical Trial Navigator
      • EU HTA regulation
  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Patient guides
  • News
  • European Myeloma Day

PopUp

  • This field is for validation purposes and should be left unchanged.